Nizar M. Tannir, M.D., FACP

Peer-Reviewed Articles

1. Tannir NM, Formiga MN, Penkov K, Kislov N, Vasiliev A, Gunnar Skare N, Hong W, Dai S, Tang L, Qureshi A, Zalevsky J, Tagliaferri MA, George D, Agarwal N, Pal S. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). J Clin Oncol 42(23):JCO2302082, 2024. e-Pub 2024. PMID: 38838287.
2. Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM. Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol 19(8):1061-1072, 2024. e-Pub 2024. PMID: 38848131.
3. Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. e-Pub 2024. PMID: 39098455.
4. Pant S, Cho BC, Kyriakopoulos CE, Spira A, Tannir N, Werner TL, Yan X, Neuteboom S, Chao R, Goel S. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Invest New Drugs. e-Pub 2024. PMID: 39168901.
5. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist 29(7):589-595, 2024. e-Pub 2024. PMID: 38478923.
6. Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov 14(7):OF1-OF14, 2024. e-Pub 2024. PMID: 38583184.
7. Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Eur Urol 86(1):4-9, 2024. e-Pub 2024. PMID: 38582713.
8. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. e-Pub 2024. PMID: 38965214.
9. Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol. e-Pub 2024. PMID: 39013742.
10. Mantia CM, Jegede OA, Plimack ER, Powles T, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albigès L, Rosenblatt L, Atkins MB, Regan MM, McDermott DF. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. J Immunother Cancer 12(7), 2024. e-Pub 2024. PMID: 39060019.
11. Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer 22(3):102065, 2024. e-Pub 2024. PMID: 38556389.
12. Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albigès L. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. Eur J Cancer 204:114048, 2024. e-Pub 2024. PMID: 38653033.
13. Brugarolas J, Obara G, Beckermann KE, Rini B, Lam ET, Hamilton J, Schluep T, Yi M, Wong S, Mao ZL, Gamelin E, Tannir NM. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clin Cancer Res 30(11):2402-2411, 2024. PMID: 38652038.
14. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2023. PMID: 38035767.
15. Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 22(2):115-125.e3, 2024. e-Pub 2023. PMID: 37914609.
16. Albiges L, McGregor BA, Heng DYC, Procopio G, de Velasco G, Taguieva-Pioger N, Martín-Couce L, Tannir NM, Powles T. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat Rev 122:102652, 2024. e-Pub 2023. PMID: 37980876.
17. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
18. Lu X, Tawanaie Pour Sedehi N, Su X, Yan F, Alhalabi O, Tannir NM, Malouf GG. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. Oncologist 28(11):1009-1013, 2023. e-Pub 2023. PMID: 37315151.
19. Msaouel P, Genovese G, Tannir NM. Renal Cell Carcinoma of Variant Histology: Biology and Therapies. Hematol Oncol Clin North Am 37(5):977-992, 2023. e-Pub 2023. PMID: 37244822.
20. Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res 29(19):4002-4015, 2023. e-Pub 2023. PMID: 37527013.
21. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
22. Feils AS, Erbe AK, Birstler J, Kim K, Hoch U, Currie SL, Nguyen T, Yu D, Siefker-Radtke AO, Tannir N, Tolaney SM, Diab A, Sondel PM. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunol Immunother 72(7):2099-2111, 2023. e-Pub 2023. PMID: 36823323.
23. Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
24. Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568622.
25. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
26. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med 13(5):e1267, 2023. PMID: 37226898.
27. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
28. Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
29. Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun 14(1):3034, 2023. e-Pub 2023. PMID: 37236926.
30. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
31. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. e-Pub 2023. PMID: 36863962.
32. McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol 9(1):102-111, 2023. PMID: 36480191.
33. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. e-Pub 2022. PMID: 35979929.
34. Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 10(12), 2022. PMID: 36549781.
35. Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol 82(4):365-373, 2022. e-Pub 2022. PMID: 35643589.
36. Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol 8(10):1411-1418, 2022. PMID: 36048457.
37. Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 72(5):454-489, 2022. e-Pub 2022. PMID: 35708940.
38. Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 33:100640. e-Pub 2022. PMID: 36174377.
39. Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, Goodman OB, Nikolinakos PG, Kalebasty AR, Zakharia Y, Zhang Z, Parmar H, Akella L, Orford K, Tannir NM. Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. Clin Cancer Res 28(15):3248-3255, 2022. e-Pub 2022. PMID: 35576438.
40. Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128(11):2085-2097, 2022. e-Pub 2022. PMID: 35383908.
41. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation. BJU Int 129(5):610-620, 2022. e-Pub 2021. PMID: 34228889.
42. Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. Clin Cancer Res 28(8):1540-1548, 2022. e-Pub 2022. PMID: 35140121.
43. Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer 10(4), 2022. PMID: 35444058.
44. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
45. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
46. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol 81(3):266-271, 2022. e-Pub 2021. PMID: 34750035.
47. Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res 28(5):831-839, 2022. e-Pub 2021. PMID: 34965942.
48. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
49. Schmidinger M, Motzer RJ, Rolland F, Staehler M, Rink M, Retz M, Csoszi T, McCaffrey JA, De Giorgi U, Caserta C, Duran I, Benzaghou F, Clary DO, Albiges L, Choueiri TK, Tannir NM. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta Oncol 61(1):1-6, 2022. e-Pub 2021. PMID: 34736367.
50. Vogelzang NJ, Monnette AM, Wang Y, Wan Y, Xie Y, Robert NJ, Tannir NM. Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting. Clin Genitourin Cancer 19(6):531-539, 2021. e-Pub 2021. PMID: 34112611.
51. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39(12):837.e9-837.e17, 2021. e-Pub 2021. PMID: 34551888.
52. Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res 27(24):6687-6695, 2021. e-Pub 2021. PMID: 34759043.
53. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
54. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
55. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
56. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
57. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
58. Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res 27(18):4994-5003, 2021. e-Pub 2021. PMID: 34285061.
59. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer 21(1):1023, 2021. e-Pub 2021. PMID: 34525968.
60. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
61. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer 21(1):904, 2021. e-Pub 2021. PMID: 34364385.
62. Thouvenin J, Martínez Chanzá N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG. Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. Cancers (Basel) 13(17), 2021. e-Pub 2021. PMID: 34503152.
63. Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer 149(2):403-408, 2021. e-Pub 2021. PMID: 33709428.
64. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
65. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
66. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and VEGFR-TKI therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
67. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 19(2):103-116, 2021. e-Pub 2020. PMID: 33358151.
68. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
69. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
70. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst 113(3):234-243, 2021. e-Pub 2020. PMID: 32359162.
71. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
72. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol 4(1):102-111, 2021. e-Pub 2019. PMID: 31786162.
73. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2020. PMID: 32675015.
74. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
75. Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?. Expert Opin Ther Targets 25(2):1-11, 2021. e-Pub 2020. PMID: 33356674.
76. Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33572149.
77. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res 27(1):78-86, 2021. e-Pub 2020. PMID: 32873572.
78. Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res 81(2):332-343, 2021. e-Pub 2020. PMID: 33158812.
79. Su X, Lu X, Bazai SK, Compérat E, Mouawad R, Yao H, Rouprêt M, Spano JP, Khayat D, Davidson I, Tannir NN, Yan F, Malouf GG. Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biol 22(1):7, 2021. e-Pub 2021. PMID: 33397444.
80. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
81. Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival Following Cytoreductive Nephrectomy: A Comparison of Existing Prognostic Models. BJU Int 126(6):745-753, 2020. e-Pub 2020. PMID: 32623821.
82. Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger C, Gurney H, Grimm M, Tomita Y, Castellano D, Rini B, Choueiri T, Shally Saggi S, Mchenry M, Motzer R. Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés. Prog Urol 30(13):785-786, 2020. PMID: 33157721.
83. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6), 2020. PMID: 33229506.
84. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5(6), 2020. PMID: 33246931.
85. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol 3(5):687-694, 2020. e-Pub 2019. PMID: 31272939.
86. Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050651.
87. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer 126(17):3950-3960, 2020. e-Pub 2020. PMID: 32515845.
88. Hasanov E, Gao J, Tannir NM. The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results. Cancer J 26(5):419-431, 2020. PMID: 32947310.
89. Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov 10(8):1158-1173, 2020. e-Pub 2020. PMID: 32439653.
90. Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 8(2), 2020. PMID: 32661118.
91. Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. e-Pub 2020. PMID: 32673417.
92. Gupta S, Kang HC, Sun J, Matrana MR, Tannir NM, Choi H. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdom Radiol (NY) 45(6):1872-1882, 2020. e-Pub 2019. PMID: 31822966.
93. Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G, DeBenedette M, Gamble A, Plachco A, Norris MS, Horvatinovich J, Tcherepanova IY, Nicolette CA, Wood CG, ADAPT study group. Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res 26(10):2327-2336, 2020. e-Pub 2020. PMID: 32034074.
94. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
95. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
96. Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, McHenry MB, Rini BI. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol 77(4):449-453, 2020. e-Pub 2019. PMID: 31732098.
97. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75, 2020. e-Pub 2020. PMID: 31986451.
98. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. e-Pub 2019. PMID: 32162795.
99. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
100. Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treat Res Commun 23:100166. e-Pub 2020. PMID: 31935623.
101. Malouf GG, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, Compérat E, Rouprêt M, Mano R, Blum KA, Yao H, Mouawad R, Spano JP, Khayat D, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep 10(1):701, 2020. e-Pub 2020. PMID: 31959902.
102. Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol 7(5):1777060, 2020. e-Pub 2020. PMID: 32944636.
103. Hasanov E, Tidwell RSS, Fernandez P, Park L, McMichael C, Tannir NM, Jonasch E. Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clin Genitourin Cancer 17(6):451-456, 2019. e-Pub 2019. PMID: 31439537.
104. Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Paul Nathan , Porta C, Grünwald V, Dezzani L, Han J, Tannir NM. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 17(6):425-435.e4, 2019. e-Pub 2019. PMID: 31601514.
105. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol 32(11):1698-1707, 2019. e-Pub 2019. PMID: 31231128.
106. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 20(11):1544-1555, 2019. e-Pub 2019. PMID: 31563517.
107. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM, CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370-1385, 2019. e-Pub 2019. PMID: 31427204.
108. Ning MS, Deegan BJ, Ho JC, Chapman BV, Bishop AJ, Allen PK, Tannir NM, Amini B, Briere TM, Wang XA, Tatsui CE, Rhines LD, Brown PD, Li J, Ghia AJ. Low incidence of late failure and toxicity after spine stereotactic radiosurgery: Secondary analysis of phase I/II trials with long-term follow-up. Radiother Oncol 138:80-85, 2019. e-Pub 2019. PMID: 31252298.
109. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. e-Pub 2019. PMID: 31501271.
110. Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discov 9(6):711-721, 2019. e-Pub 2019. PMID: 30988166.
111. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
112. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer 17(1):1-6, 2019. e-Pub 2018. PMID: 30287223.
113. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220.e9, 2019. PMID: 30753823.
114. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
115. Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. J Immunother Cancer 6(1):159, 2018. e-Pub 2018. PMID: 30591082.
116. Atkins MB, Tannir NM. Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Cancer Treat Rev 70:127-137, 2018. e-Pub 2018. PMID: 30173085.
117. Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol 188(11):2487-2496, 2018. e-Pub 2018. PMID: 30201497.
118. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
119. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell 34(5):775-791.e3, 2018. PMID: 30423297.
120. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 36(16):1588-1593, 2018. e-Pub 2018. PMID: 29641297.
121. Msaouel P, Tannir NM, Walker CL. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res 24(9):2044-2049, 2018. e-Pub 2018. PMID: 29440190.
122. Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist 23(5):540-555, 2018. e-Pub 2018. PMID: 29487224.
123. Tannir N, Hammers H, Amin A. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. Curr Med Res Opin 34(5):1-7, 2018. e-Pub 2018. PMID: 29297707.
124. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis 39(6):752-757, 2018. PMID: 29635281.
125. Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care 16(2):1-9, 2018. e-Pub 2017. PMID: 28262086.
126. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378(14):1277-1290, 2018. e-Pub 2018. PMID: 29562145.
127. Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol 36(8):JCO2017752170, 2018. e-Pub 2018. PMID: 29377755.
128. Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20(1):32-43, 2018. e-Pub 2017. PMID: 29190493.
129. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
130. Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A. Recommendations for the Management of Rare Kidney Cancers. Eur Urol 72(6):974-983, 2017. e-Pub 2017. PMID: 28720391.
131. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 123(24):4823-4831, 2017. e-Pub 2017. PMID: 28832979.
132. Kang HC, Gupta S, Wei W, Lu L, Matrana MR, Tannir NM, Choi H. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. AJR Am J Roentgenol 209(6):1278-1284, 2017. e-Pub 2017. PMID: 29064751.
133. Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, Tam AL. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control. J Bone Joint Surg Am 99(22):1916-1926, 2017. PMID: 29135665.
134. Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology 26(9):1361-1368, 2017. e-Pub 2016. PMID: 27145447.
135. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies Over Three Decades: Comparison Between the Cytokine (1987-2005) and the Targeted Therapy (2006-2015) Eras. J Urol 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
136. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer 123(18):3617-3627, 2017. e-Pub 2017. PMID: 28543182.
137. Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X. Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-related Genes. Cancer Epidemiol Biomarkers Prev 26(9):1436-1442, 2017. e-Pub 2017. PMID: 28626070.
138. Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG. NSD1 inactivation and SETD2 mutation drive a convergence toward loss-of-function of H3K36 writers in clear-cell renal cell carcinomas. Cancer Res 77(18):4835-4845, 2017. e-Pub 2017. PMID: 28754676.
139. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw 15(9):1111-1120, 2017. PMID: 28874596.
140. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. e-Pub 2017. PMID: 28870517.
141. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B loss exacerbates the development of chromophobe renal cell carcinomas. Cancer Res. e-Pub 2017. PMID: 28807937.
142. Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep 7(1):8540, 2017. e-Pub 2017. PMID: 28819235.
143. Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X. Glycemic Index, Glycemic Load, and Carbohydrate Intake in Association with Risk of Renal Cell Carcinoma. Carcinogenesis. e-Pub 2017. PMID: 28968893.
144. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract 13(7):414-421, 2017. PMID: 28697319.
145. Wang Z, Kim TB, Peng B, Karam JA, Creighton CJ, Joon AY, Kawakami F, Trevisan P, Jonasch E, Chow CW, Rodriguez-Canales J, Tamboli P, Tannir NM, Wood CG, Monzon FA, Baggerly KA, Varella-Garcia M, Czerniak B, Wistuba II, Mills GB, Shaw K, Chen K, Sircar K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape. Clin Cancer Res. e-Pub 2017. PMID: 28710314.
146. Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, Grégoire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Tannir NM, Leroy X. Incidence, clinicopathologic features, and fusion transcript landscape of translocation renal cell carcinomas. Histopathology 70(7):1089-1097, 2017. e-Pub 2017. PMID: 28106924.
147. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
148. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget 8(26):42149-42158, 2017. e-Pub 2017. PMID: 28178674.
149. Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer. e-Pub 2017. PMID: 28711490.
150. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol 40(2):189-193, 2017. e-Pub 2014. PMID: 25222071.
151. Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer 15(2):e205-e208, 2017. e-Pub 2016. PMID: 27568124.
152. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN, Tannir NM. A Randomized Phase 2 Study of MK-2206 versus Everolimus in Refractory Renal Cell Carcinoma. Ann Oncol 28(4):804-808, 2017. e-Pub 2017. PMID: 28049139.
153. de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist 22(3):286-292, 2017. e-Pub 2017. PMID: 28220024.
154. Tannir NM, Schwab G, Grünwald V. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Curr Oncol Rep 19(2):14, 2017. PMID: 28247252.
155. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer 116(1):77-84, 2017. e-Pub 2016. PMID: 27907930.
156. Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res 22(24):6236-6246, 2016. e-Pub 2016. PMID: 27256309.
157. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK. Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups. Cancer Immunol Res 4(10):820-822, 2016. e-Pub 2016. PMID: 27538576.
158. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role Of Metastasectomy In Patients With Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol 196(3):678-84, 2016. e-Pub 2016. PMID: 27036304.
159. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience. BJU Int 118(2):264-71, 2016. e-Pub 2015. PMID: 26573089.
160. Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol 70(2):348-57, 2016. e-Pub 2016. PMID: 26895810.
161. Tao R, Bishop AJ, Brownlee Z, Allen PK, Settle SH, Chang EL, Wang X, Amini B, Tannir NM, Tatsui C, Rhines LD, Brown PD, Ghia AJ. Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials. Int J Radiat Oncol Biol Phys 95(5):1405-13, 2016. e-Pub 2016. PMID: 27209509.
162. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. e-Pub 2016. PMID: 27528724.
163. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917-27, 2016. e-Pub 2016. PMID: 27279544.
164. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2015. PMID: 26032863.
165. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-97, 2016. e-Pub 2015. PMID: 26364599.
166. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 69(5):866-74, 2016. e-Pub 2015. PMID: 26626617.
167. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol 34(5):237.e19-26, 2016. e-Pub 2015. PMID: 26707613.
168. Ghia AJ, Chang EL, Bishop AJ, Pan HY, Boehling NS, Amini B, Allen PK, Li J, Rhines LD, Tannir NM, Tatsui CE, Brown PD, Yang JN. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials. J Neurosurg Spine 24(5):1-8, 2016. e-Pub 2016. PMID: 26799117.
169. Land JD, Chen AH, Atkinson BJ, Cauley DH, Tannir NM. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract 22(2):235-41, 2016. e-Pub 2014. PMID: 25505255.
170. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X. Genomic DNA hypomethylation and risk of renal cell carcinoma: A case-control study. Clin Cancer Res 22(8):2074-82, 2016. e-Pub 2015. PMID: 26655847.
171. Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene 35(12):1565-74, 2016. e-Pub 2015. PMID: 26073078.
172. Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med 109(3):98-105, 2016. e-Pub 2016. PMID: 26933155.
173. Amini B, Beaman CB, Madewell JE, Allen PK, Rhines LD, Tatsui CE, Tannir NM, Li J, Brown PD, Ghia AJ. Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials. AJNR Am J Neuroradiol 37(2):387-92, 2016. e-Pub 2015. PMID: 26494690.
174. Lee SH, Tatsui CE, Ghia AJ, Amini B, Li J, Zavarella SM, Tannir NM, Brown PD, Rhines LD. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials. J Neurooncol 126(3):509-17, 2016. e-Pub 2015. PMID: 26643804.
175. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer 122(1):108-15, 2016. e-Pub 2015. PMID: 26551148.
176. Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer 16(1):254, 2016. e-Pub 2016. PMID: 27026229.
177. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. e-Pub 2016. PMID: 27330809.
178. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26(12):2507-8, 2015. e-Pub 2015. PMID: 26487577.
179. Thekdi SM, Milbury K, Spelman A, Wei Q, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Cohen L. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology 24(11):1477-84, 2015. e-Pub 2015. PMID: 25690556.
180. Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget 6(37):39865-76, 2015. e-Pub 2015. PMID: 26431491.
181. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373(19):1814-23, 2015. e-Pub 2015. PMID: 26406150.
182. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 33(10):427.e17-23, 2015. e-Pub 2015. PMID: 26004164.
183. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/High-Dose Chemotherapy with Autologous Stem-Cell Transplant for Poor-Risk Relapsed or Refractory Germ-Cell Tumors. Ann Oncol 26(10):2125-32, 2015. e-Pub 2015. PMID: 26199392.
184. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist 20(10):1140-8, 2015. e-Pub 2015. PMID: 26306901.
185. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RGW, Tannir NM, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cellcarcinomas are molecularly similar to, but distinct from,non-sarcomatoid renal carcinomas. J Pathology 1(4):212-224, 2015. e-Pub 2015.
186. Yennurajalingam S, Reddy A, Tannir NM, Chisholm GB, Lee RT, Lopez G, Escalante CP, Manzullo EF, Frisbee Hume S, Williams JL, Cohen L, Bruera E. High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue: A Preliminary Report. Integr Cancer Ther 14(5):419-27, 2015. e-Pub 2015. PMID: 25873296.
187. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
188. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol 28(9):1225-35, 2015. e-Pub 2015. PMID: 26111976.
189. Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. Int J Radiat Oncol Biol Phys 93(1):118-25, 2015. e-Pub 2015. PMID: 26130231.
190. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy. J Urol 194(2):316-22, 2015. e-Pub 2015. PMID: 25758610.
191. Bishop AJ, Tao R, Rebueno NC, Christensen EN, Allen PK, Wang XA, Amini B, Tannir NM, Tatsui CE, Rhines LD, Li J, Chang EL, Brown PD, Ghia AJ. Outcomes for Spine Stereotactic Body Radiation Therapy and an Analysis of Predictors of Local Recurrence. Int J Radiat Oncol Biol Phys 92(5):1016-26, 2015. e-Pub 2015. PMID: 26025777.
192. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
193. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol 67(2):149-56, 2015. e-Pub 2015. PMID: 25645343.
194. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 34(19):2450-60, 2015. e-Pub 2014. PMID: 24998849.
195. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol 33(4):166.e21-9, 2015. e-Pub 2015. PMID: 25700975.
196. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?. Urol Case Rep 27(2):18-20, 2015. PMID: 26120560.
197. Prinsloo S, Wei Q, Scott SM, Tannir N, Jonasch E, Pisters L, Cohen L. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med 38(1):48-56, 2015. e-Pub 2014. PMID: 24935017.
198. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer 13(1):e19-26, 2015. e-Pub 2014. PMID: 25087088.
199. Melkonian SC, Wang X, Gu J, Matin SF, Tannir NM, Wood CG, Wu X. Mitochondrial DNA Copy Number in Peripheral Blood Leukocytes and the Risk of Clear Cell Renal Cell Carcinoma. Carcinogenesis 36(2):249-55, 2015. e-Pub 2014. PMID: 25524925.
200. Shu X, Purdue MP, Ye Y, Wood CG, Chen M, Wang Z, Albanes D, Pu X, Huang M, Stevens VL, Diver WR, Gapstur SM, Virtamo J, Chow WH, Tannir NM, Dinney CP, Rothman N, Chanock SJ, Wu X. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget 6(6):4097-109, 2015. PMID: 25784652.
201. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9(1):32-43, 2015. e-Pub 2014. PMID: 25126716.
202. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2014. PMID: 25155428.
203. Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V. Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience 2(2):187-92, 2015. e-Pub 2015. PMID: 25859559.
204. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Tannir NM. Neuroendocrine Tumors of the Kidney: A Single Institution Experience. Clin Genitour Cancer 12(6):422-27, 2014.
205. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246-57, 2014. e-Pub 2014. PMID: 25142258.
206. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 66(5):874-80, 2014. e-Pub 2014. PMID: 24560330.
207. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget 5(21):10280-92, 2014. PMID: 25373733.
208. Pan HY, Allen PK, Wang XS, Chang EL, Rhines LD, Tatsui CE, Amini B, Wang XA, Tannir NM, Brown PD, Ghia AJ. Incidence and Predictive Factors of Pain Flare After Spine Stereotactic Body Radiation Therapy: Secondary Analysis of Phase 1/2 Trials. Int J Radiat Oncol Biol Phys 90(4):870-6, 2014. e-Pub 2014. PMID: 25227497.
209. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience. Clin Genitourin Cancer 12(5):348-53, 2014. e-Pub 2014. PMID: 24565697.
210. Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint Association of Genome-Wide Association Study-Identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites. Am J Epidemiol 180(5):499-507, 2014. e-Pub 2014. PMID: 25053674.
211. Tu SM, Bilen MA, Tannir NM. The scientific method: pillar and pitfall of cancer research. Cancer Med 3(4):1035-7, 2014. e-Pub 2014. PMID: 24711219.
212. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM. Next generation sequencing of translocation renal cell carcinomas reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes. Clin Cancer Res 20(15):4129-40, 2014. e-Pub 2014. PMID: 24899691.
213. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol 192(1):36-42, 2014. e-Pub 2014. PMID: 24518767.
214. Burch-Smith R, Tannir NM, Resetkova E, Tamboli P, Rao P. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow up. Chin J Cancer 33(7):351-5, 2014. e-Pub 2014. PMID: 24589208.
215. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelsohn DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(3):167-177.e2, 2014. e-Pub 2013. PMID: 24365125.
216. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes in metastatic renal cell carcinoma patients treated with alternative sunitinib schedules. J Urol 191(3):611-8, 2014. e-Pub 2013. PMID: 24018239.
217. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol 32(7):663-70, 2014. e-Pub 2014. PMID: 24470003.
218. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113(3):376-82, 2014. e-Pub 2013. PMID: 24053120.
219. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(1):221-9, 2014. e-Pub 2013. PMID: 24170769.
220. Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 36(6):620-4, 2013. e-Pub 2012. PMID: 22892430.
221. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 36(5):450-4, 2013. e-Pub 2012. PMID: 22706175.
222. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 2013. e-Pub 2013. PMID: 23810246.
223. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19(17):4673-4684, 2013. e-Pub 2013. PMID: 23817689.
224. Conter HJ, Lim ZD, Ng CS, Millikan RE, Tannir NM. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: A case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer 11(3):370-3, 2013. e-Pub 2013. PMID: 23665133.
225. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076-82, 2013. e-Pub 2013. PMID: 23897970.
226. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, Thompson EJ, TCGA Network, Meric-Bernstam F, Medeiros LJ, Weinstein JN, Su X. Landscape of DNA virus associations across human malignant cancers using RNA-seq: An analysis of 3775 cases. J Virol 87(16):8916-26, 2013. e-Pub 2013. PMID: 23740984.
227. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
228. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 2013. e-Pub 2013. PMID: 23675612.
229. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol 36(3):258-60, 2013. e-Pub 2012. PMID: 22441343.
230. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: A 2-year prospective study. Eur Urol 63(6):1122-1127, 2013. e-Pub 2013. PMID: 23419322.
231. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63(5):947-52, 2013. e-Pub 2012. PMID: 23273681.
232. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 111(6):997-1005, 2013. e-Pub 2013. PMID: 23510233.
233. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst 105(6):424-32, 2013. e-Pub 2013. PMID: 23378641.
234. Chen Y, Yao H, Thompson EJ, Tannir NM, Weinstein JN, Su X. VirusSeq: Software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics 29(2):266-7, 2013. e-Pub 2012. PMID: 23162058.
235. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152-61, 2012. e-Pub 2012. PMID: 22692704.
236. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 110(11):1742-6, 2012. e-Pub 2012. PMID: 22503066.
237. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 2012. e-Pub 2012. PMID: 22771265.
238. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, 2012. e-Pub 2010. PMID: 20933444.
239. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer 10(3):210-2, 2012. e-Pub 2012. PMID: 22503609.
240. Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol 36(4):583-8, 2012. e-Pub 2012. PMID: 22301499.
241. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 2012. e-Pub 2011. PMID: 21464158.
242. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 7(8):e42324, 2012. e-Pub 2012. PMID: 22870317.
243. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 2012. e-Pub 2019. PMID: 32018383.
244. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22(12):2661-6, 2011. PMID: 22105611.
245. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction Is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273-9, 2011. e-Pub 2011. PMID: 21784574.
246. Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer 9(2):137-9, 2011. e-Pub 2011. PMID: 21831725.
247. Milbury K, Tannir NM, Cohen L. Treatment-related optimism protects quality of life in a phase II clinical trial for metastatic renal cell carcinoma. Ann Behav Med 42(3):313-20, 2011. e-Pub 2011. PMID: 21822749.
248. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9(2):81-8, 2011. e-Pub 2011. PMID: 21958521.
249. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47(18):2706-14, 2011. e-Pub 2011. PMID: 22078932.
250. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964-71, 2011. e-Pub 2011. PMID: 21621907.
251. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear cell renal cell carcinoma associated with poor prognosis. Mod Pathol 24(11):1470-9, 2011. e-Pub 2011. PMID: 21725288.
252. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958-65, 2011. e-Pub 2011. PMID: 21484781.
253. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68(4):889-96, 2011. e-Pub 2011. PMID: 21290244.
254. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. Hematol Oncol Clin North Am 25(4):853-869, 2011. PMID: 21763971.
255. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol 6(3):144-50, 2011. PMID: 21827393.
256. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 2011. PMID: 21707288.
257. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 2011. e-Pub 2010. PMID: 21115604.
258. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. BJU Int 107(5):741-7, 2011. e-Pub 2010. PMID: 21355978.
259. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 29(8):e203-5, 2011. e-Pub 2010. PMID: 21172884.
260. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2011. e-Pub 2010. PMID: 21167518.
261. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10-5, 2011. e-Pub 2010. PMID: 20952123.
262. Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, Guo CC. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 42(1):146-50, 2011. e-Pub 2010. PMID: 20971497.
263. Dutcher JP, Tannir N, Bellmunt J, Escudier B. Experience with sorafenib and the elderly patient. Med Oncol 27(4):1359-70, 2010. e-Pub 2009. PMID: 20043216.
264. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 2010. PMID: 21110755.
265. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 2010. e-Pub 2010. PMID: 20846689.
266. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116(22):5219-25, 2010. e-Pub 2010. PMID: 20665500.
267. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol 184(5):1877-81, 2010. e-Pub 2010. PMID: 20850148.
268. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 21(8):1599-606, 2010. e-Pub 2010. PMID: 20089566.
269. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer 116(14):3378-88, 2010. PMID: 20564061.
270. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 5(2):113-8, 2010. e-Pub 2010. PMID: 20625844.
271. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811-5, 2010. e-Pub 2010. PMID: 20052472.
272. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 194(1):166-71, 2010. PMID: 20028919.
273. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 2010. e-Pub 2009. PMID: 19862815.
274. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125(10):2342-8, 2009. e-Pub 2009. PMID: 19521957.
275. Hong D, Sebti S, Newman R, Blaskovich M, Ye L, Gagel R, Moulder S, Wheler J, Naing A, Tannir N, Ng C, Sherman S, El-Naggar A, Khan R, Trent J, Wright J, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 2009. e-Pub 2009. PMID: 19903778.
276. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in metastatic renal cell cancer: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 2009. e-Pub 2009. PMID: 19541791.
277. Jonasch E, Wood CG, Matin SF, Tu S-M, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
278. Rodney A, Gombos D, Fuller G, Pagliaro LC, Tannir N. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol 32(4):448-9, 2009. PMID: 19657240.
279. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 2009. e-Pub 2009. PMID: 19338544.
280. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood C, Sandler CM. Papillary renal cell carcinoma: Radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54; discussion 755-7, 2009. PMID: 19448113.
281. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859-66, 2009. e-Pub 2009. PMID: 19241453.
282. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-1317, 2009. PMID: 19156903.
283. Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM. Ischemic optic neuropathy associated with low dose interferon alfa: Report of two cases. Am J Clin Oncol 32(1):86-87, 2009. PMID: 19194130.
284. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 18(3):801-807, 2009. e-Pub 2009. PMID: 19240244.
285. Dubauskas Z, Kunishige J, Prieto VG, Kantrow SM, Jonasch E, Hwy P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 2009. PMID: 19213663.
286. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high risk renal cell carcinoma. Urology 73(2):337-41, 2009. e-Pub 2008. PMID: 18950837.
287. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Horne E, Tannir N, Groshen S, Jones P, Yang A, Issa J-P. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3), 2009. PMID: 19421002.
288. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 29(11):2112-2119, 2008. e-Pub 2008. PMID: 18711149.
289. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance - Review. AJR Am J Roentgenol 191(4):1220-1230. Review, 2008. PMID: 18806169.
290. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine in metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 2008. e-Pub 2008. PMID: 18635226.
291. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: A case report. Clin Genitourin Cancer 6(2):122-123, 2008. PMID: 18824436.
292. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu SM. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer 6(2):128-130, 2008. PMID: 18824438.
293. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9, 2008. PMID: 18836336.
294. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144(6):779-82, 2008. PMID: 18559769.
295. Jonasch E, Wood C, Tamboli P. Pagliaro LC, Tu SM, Kim J, Sirvastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 2008. e-Pub 2008. PMID: 18362942.
296. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JD, Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112(11):2500-8, 2008. PMID: 18386829.
297. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, 2008. e-Pub 2008. PMID: 18485389.
298. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 26(6):595-596, 2008. e-Pub 2008. PMID: 18367105.
299. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at post-chemotherapy retroperitoneal lymph node dissection: Can we predict patients at risk of disease progression?. Cancer 110(12):2700-2708, 2007. PMID: 17948916.
300. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 70(6):1173-1178, 2007. PMID: 18158041.
301. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 2007. e-Pub 2007. PMID: 17427204.
302. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with non-clear histology. J Urol 178(5):1896-1900, 2007. e-Pub 2007. PMID: 17868729.
303. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 110(8):1729-1737, 2007. PMID: 17786954.
304. Small EJ, Fontana J, Tannir N, DiPaola R, Wilding G, Rubin M, Bailey Iacona R, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 100(4):765-769, 2007. PMID: 17822457.
305. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-5824, 2007. PMID: 17908974.
306. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4 Pt 1):1492-1496, 2007. e-Pub 2007. PMID: 17707063.
307. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(8):975-985, 2007. PMID: 17640602.
308. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794-801, 2007. PMID: 17671020.
309. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M.D. Anderson Cancer experience. J Urol 177(4):1330-1334; discussion 1334, 2007. PMID: 17382725.
310. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-138, 2007. PMID: 17162023.
311. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22 Pt 1):6689-6695, 2007. PMID: 18006769.
312. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 2006. PMID: 17029276.
313. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-1490, 2006. PMID: 16944541.
314. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: Can it be predicted using clinical parameters?. Cancer 107(7):1503-1510, 2006. PMID: 16944534.
315. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106(10):2143-2147, 2006. PMID: 16598751.
316. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. PMID: 16795067.
317. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-688, 2005. PMID: 15872323.
318. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials 2(6):467-78, 2005. PMID: 16422307.
319. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-3836, 2003. e-Pub 2003. PMID: 12881308.
320. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol 170(1):178-179, 2003. PMID: 12796677.
321. Tannir NM, Kantarjian H. Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia. Leuk Lymphoma 41(1-2):217-220, 2001. PMID: 11342378.
322. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma 39(5-6):647-650, 2000. PMID: 11342349.
323. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5(4):556-561, 1987. PMID: 3559649.
324. Kouttab N, Tannir N, Pathak S, Berger A, Sahasrabuddhe CG, Maizel AL. Establishment of stable human T-T hybridomas. J Immunol Methods 77(1):165-172, 1985. PMID: 3871822.
325. Tannir N, Riggs S, Velasquez W, Samaan N, Manning J. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer 55(3):615-619, 1985. PMID: 2981152.
326. Kouttab NM, Mehta S, Morgan J, Tannir N, Sahasrabuddhe C, Maizel AL. Lymphokines and monokines as regulators of human lymphoproliferation. Clin Chem 30(9):1539-1545, 1984. PMID: 6432365.
327. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep 68(7-8):1039-1041, 1984. PMID: 6547638.
328. Tannir N, Spitzer G, Dicke K, Schell F, DiStefano A, Blumenschein G. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep 68(5):805-806, 1984. PMID: 6426793.
329. Tannir NM, Cortas N, Allam C. A functioning catecholamine-secreting vagal body tumor. A case report and review of the literature. Cancer 52(5):932-935, 1983. PMID: 6347360.
330. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol 19(8):1091-1096, 1983. PMID: 6352279.
331. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 7:432-439, 1983. PMID: 6199478.
332. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep 67(6):599-600, 1983. PMID: 6344995.
333. Uwaydah M, Tannir N, Kantarjian H, Osseiran M, Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother 23:289-292, 1983. PMID: 6220673.
334. Spitzer G, Vellekoop L, Zander A, Tannir N. Autologous bone marrow transplantation in leukemia and lymphomas. J Exp Clin Cancer Res 3:317-332, 1983.
335. Salti I, Faris A, Tannir N, Khouri K. Rapid correction by 1-alpha-hydroxycholecalciferol of hemichorea in surgical hypoparathyroidism. J Neurol Neurosurg Psychiatry 45(1):89-90, 1982. PMID: 7062078.

Invited Articles

1. Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol 29(5):521-525, 2019. PMID: 31305271.
2. Malouf GG, Joseph RW, Shah AY, Tannir NM. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol 15(5):409-418, 2017. PMID: 28591094.
3. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol 6(3):189-98, 2011. PMID: 21827388.

Other Articles

1. Spiess PE, Tannir NM Reply. Urol Oncol 27(2):218-9, 2009. PMID: 19285239.
2. Cheung YC, Tannir N, Champlin RE, Ueno NT Allogeneic hematopoietic stem-cell transplantation for metastatic RCC. Kidney Cancer J 3(3):11-20, 2005.
3. Mehta KU, Gascon P, Tannir N, Lombardo J, Robboy SJ Impaired bone marrow in AIDS. N J Med 86(8):623-627, 1989. PMID: 2685666.
4. Riggs S, Tannir N Fatal disseminated histoplasmosis in a patient with Hodgkin’s disease. The Cancer Bulletin of the University of Texas 34(4):165—167, 1982.

Editorials

1. Flippot R, Compérat E, Tannir NM, Malouf GG. Papillary Renal Cell Carcinoma: A Family Portrait. Eur Urol 73(1):79-80, 2018. PMID: 28642022.
2. Msaouel P, Malouf GG, Tannir NM. Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. Eur Urol 71(3):415-416, 2017. PMID: 27816301.

Abstracts

1. Sen S, Hess K, Hong D, Naing A, Piha-Paul S, Janku F, Fru S, Liu H, Jiang Y, Khanji R, Karp D, Tsimberidou A, Tannir N, Meric-Bernstam F, Subbiah V. Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials. Can Research 77(13 suppl), 2017.
2. Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell M, Ng CS, Slack RS, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. Can Research 77(13 suppl), 2017.
3. Tannir NM, Porta C, Gruenwald V, Choueiri TK, Ahad Q, Alfonso MC, Dezzani L, Han J, Sternberg CN. Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis. J Clin Oncol 35(suppl), 2017.
4. Tannir NM, Powles T, Escudier BJ, Donskov F, Grunwald V, Sternberg CN, Schmidinger M, Schoffski P, Szczylik C, Peltola KJ, Nosov D, Melichar B, Clary DO, Scheffold C, Motzer RJ, Choueiri TK. Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 35(suppl), 2017.
5. Nieto Y, Tu SM, Campbell MT, Bassett R, Tannir NM, Ward JF, Hofstetter WL, Jones RB, Anderson B, Gulbis AM, Ledesma C, Timmons M, Trapp M, Champlin RE, Pagliaro LC. Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT). J Clin Oncol 35(suppl), 2017.
6. Jonasch E, Gombos DS, Waguespack SG, Margott V, Liu DD, Weldon JA, Bird S, Robichaux C, Tannir NM, Henriksen-Woodson A, fuller G, McCutcheon IE, Matin SF. Phase II study of pazopanib in patients with von Hippel-Lindau disease. J Clin Oncol 35(suppl), 2017.
7. Jonasch E, Slack R, Geynisman DM, Milowsky MI, Rathmell K, Stovall S, Juarez D, Plimack ER, Tannir NM, Rini BI. Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma. J Clin Oncol 35(suppl), 2017.
8. Bernatchez C, Haymaker CL, Hurwitz ME, Kluger HM, Tetzlaff MT, Jackson N, Gergel I, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Lacucci E, Aung S, Imperiali M, Liao EJ, Bentebibel SE, Tannir NM, Hwu P, Sznol M, Diab A. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. J Clin Oncol 35(suppl), 2017.
9. Malouf GG, Flippot R, Mouawad R, Yao H, Comperat E, Roupret M, Khayat D, Spano JP, Su X, Tannir NM. Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup. J Clin Oncol 35(suppl), 2017.
10. Naing A, Infante JR, Wong DJL, Korn WM, Aljumaily R, Papadoupoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Vlasselaer PV, Brown GL, Oft M, Tannir NM. Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer. J Clin Oncol 35(suppl), 2017.
11. Diab A, Tannir NM, Bernatchez C, Haymaker CL, Bentebibel SE, Curti BD, Wong MKK, Gergel I, Tagliaferri MA, Zalevsky J, Hoch U, Ang S, Imperiale M, Cho DC, Tykodi SS, Puzanov I, Kluger HM, Hurwitz ME, Hwu P, Sznol M. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. J Clin Oncol 35(suppl), 2017.
12. Campbell MT, Bilen MA, Duran C, Altinmakas E, Dubauskas-Lim Z, Jonasch E, Tannir NM. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study. J Clin Oncol 35(suppl 6S), 2017.
13. Keskin SK, Msaouel P, Hess KR, Matin SF, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience. J Clin Oncol 35(suppl 6S), 2017.
14. Hurwitz ME, Diab A, Bernatchez C, Haymaker CL, Kluger HM, Tatzlaff MT, Gregel I, Tagliaferri M, Imperiale M, Aung S, Hoch U, Zalevsky J, Hwu P, Sznol M, Tannir NM. Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. J Clin Oncol 35(suppl 6S), 2017.
15. Jonasch e, Slack R, Geynisman DM, Milowsky MI, Rathmell K, Stovall S, Juarez D, Plimack ER, Tannir NM, Rini BI. A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma. J Clin Oncol 35(suppl 6S), 2017.
16. Naing A, Infante JF, Hecht R, Papadopoulos KP, Wong DJL, Autio KA, Falchook GS, Patel MR, Ott PA, Patnaik A, Bendell JC, Vlasselaer PV, Hong DS, Tannir NM, Oft M. Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update. J Clin Oncol 35(suppl 7s), 2017.
17. Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, schmidinger M, Heng D, Mainwaring P, Hammers H, Lee JL, Rini B, Rother B, Baer J, Mangeshkar M, Scheffold C, Hutson T, Pal S, Motzer R, Choueiri T. Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC). ESMO Congress, 2016.
18. Tannir N, Powles T, Motzer R, Rolland F, Gravis G, Staehler M, Rink M, Rtz M, Csoszi T, McCaffrey J, De Giorgi U, Caseta C, Cheporov S, Esteban Gonzalez E, Durin I, Larkin J, Berg W, Blary D, Escudier B, Choueiri T. Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). ESMO Congress, 2016.
19. Naing A, Papadoupoulos K, autio K, Ott P, Patel M, Wong D, Falchook G, Pant S, Whiteside M, Rasco D, Patnaik A, Bendell J, Bauer T, Colen R, Hong D, Van Vlasselaer P, Brown G, Oft M, Tannir N, Infante J. Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1. ESMO Congress, 2016.
20. Yennu S, Tannir NM, Williams JL, Hess KR, Frisbee-Hume S, House HL, Fossella FV, Lim ZD, Lopez G, Reddy AS, Azhar A, Wong A, Patel SM, Kaseb AO, Hwu WJ, Lu Z, cohen L, Bruera E,. Effects of high-dose Asian ginseng (Panax ginseng) to improve cancer-related fatigue: Results of a double-blind, placebo-controlled randomized controlled trial. J Clin Oncol 34(suppl 26s), 2016.
21. Mendoza-Perez J, Gu J, Tannir NM, Matin S, Karam JA, Huang M, Xiang S, Chang DW, Wood CG, Herrera LA, Wu X. Prognostic value of obesity-related genes methylation in localized renal cell carcinoma patients. Can Research 77(14), 2016.
22. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJ, Falchook GS, Patel M, Pant S, Whiteside M, Mumm JB, Chan IH, Bendell JC, Bauer TM, Janku F, Javle M, Colen RR, Tannir NM, Oft M. Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors. Can Research 77(14), 2016.
23. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Prognostic and predictive plasma cytokines and angiogenic factors (CAF) in patients (pts) with advanced non-clear cell renal cell carcinoma treated with first-line sunitinib or everolimus: Results from the ESPN trial. J Clin Oncol 34(Suppl), 2016.
24. Shah AY, Karam JA, Malouf G, Pao P, Lim Z, Jonasch E, Xiao L, Gao JJ, Vaishampayan U, Heng DY, Plimack E, Guancial E, Fung C, Lowas S, Tamboli P, Sircar K, Matin S, Rathmell K, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. J Clin Oncol 34(Suppl), 2016.
25. Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M, Doleman S, Blakemore SJ, Clawson A, Daigle S, Tang J, Ho PTC, Demetri GD. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol 34(Suppl), 2016.
26. Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, Iliopoulos O, Owonikoko TK, Patel MR, McKaye R, Infante JR, Voss MH, Harding JJ. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). J Clin Oncol 34(Suppl), 2016.
27. Naing A, Papadopoulos KP, Infante JR, Wong DJL, Autio KA, Ott PA, Falchook GS, Patel MR, Pant S, Patniak A, Mumm JB, Whiteside M, Chan IH, Bendell JC, Bauer TM, Janku F, Colen RR, Tannir NM, Vlasselaer PV, Oft M. Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. J Clin Oncol 34(Suppl), 2016.
28. Malour G, Su X, Zhang J, Ho TH, Lu Y, Raynal NJM, Karam JA, Tamboli P, Allanick F, Mouawad R. Khayat D, Wood CG, Jelinek J, Tannir NM. DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny. J Clin Oncol 34(Suppl), 2016.
29. Gao JJ, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34(Suppl), 2016.
30. Choueiri TK, Poweles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Aftab DT, Hessel C, Scheffold C, Schwab G, Pal SK, Hutson TE, Motzer RJ. Overall survival in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 34(Suppl), 2016.
31. Jonasch E, Hoang A, Sun M, Zhou L, Ding Z, Zhang X, Bai S, Tannir NM, Liu X. Sunitinib to upregulate IFNg-STAT1 signaling and to increase indoleamine 2,3-dioxygenase (IDO) expression in renal cell carcinoma (RCC). J Clin Oncol 34(suppl 2S), 2016.
32. Thomas AZ, Abidi M, Slack R, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation: A matched controlled analysis. J Clin Oncol 34(suppl 2S), 2016.
33. Malouf GG, Su X, Zhang J, Ho TH, Lu Y, Raynal NJM, Karam JA, Tamboli P, Allanick F, Mouawad R, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA methylation signature to define cell ontogeny of renal cell carcinomas. J Clin Oncol 34(suppl 2S), 2016.
34. Malour GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Mouawad R, Pal SK, Su X, Sircar K, Tamboli P, JOnasch E, Tannir NM, Wood CG, Karam JA. Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations. J Clin Oncol 34(suppl 2S), 2016.
35. Gao JJ, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34(suppl 2S), 2016.
36. Kawakami F, Sircar K, Rodriguez-Canales J, Tamboli P, Tannir NM, Jonasch E, Wistuba I, Wood CG, Karam JA. Expression of PD-1 and PD-L1 in patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 34(suppl 2S), 2016.
37. Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK. Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 34(suppl 2S), 2016.
38. Tannir NM, Figlin RA, Gore E, Michaelson D, Motzer RJ, Porta C, Rini BI, Hoang CJ, Lin X, Escudier B. Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC). J Clin Oncol 34(suppl 2s), 2016.
39. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in renal cell carcinoma etiology. Cancer Res 75(suppl 15), 2015.
40. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin S, Karam JA. MicroRNA expression links obesity and recurrence in renal cell carcinoma. Cancer Res 75(suppl 15), 2015.
41. Sanchez-Espirdion B, Tannir NM, Matin SF, Karam JA, Huang M, Wood CG, Wu X, Gu J. Detection of recurrent renal cell carcinoma biomarkers by metabolite ratios. Can Research 75(suppl 15), 2015.
42. Mendoza-Perez J, Gu J, Tannir NM, Matin S, Karam JA, Chang DW, Herrera LA, Wood CG, Wu X. Genomic DNA hypomethylation as an independent risk factor for renal cell carcinoma. Can Research 75(suppl 15), 2015.
43. Malouf GG, Zhang J, Spano JP, Comperat E, Tannir NM, Thompson EK, Weinstein JN, Tripathy D, Khayat D, Su X. Long noncoding RNA subtype classification of human prostate adenocarcinomas. Can Research 75(suppl 15), 2015.
44. de Valasco G, Fay AP, Culhane A, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Rathmell K, Albiges LK, Hsieh J, Heng KYC, Signoretti S, Choueiri TK. Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. J Clin Oncol 33(suppl), 2015.
45. Ochoa A, Zhang J, Choi W, Malouf G, Thompson E, Weinstein J, Tannir NM, Dinney C, McConkey D, Su X. The Long non-coding RNA SNHG18 promotes PPARy function and "luminal" gene expression in muscle-invasive bladder cancer. J Urol 193(4):e923, 2015. e-Pub 2015.
46. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33(suppl 7), 2015.
47. Adibi M, Thomas AZ, Borregales L, Merrill MM, SircarK, Tamboli P, Slack R, Chen HC, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in sarcomatoid renal cell carcinoma. J Clin Oncol 33(suppl 7), 2015.
48. Borregales, L, Kim DY, Qiao W, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Outcomes and prognosticators in patients with pathologic T4 renal cell carcinoma. J Clin Oncol 33(suppl 7), 2015.
49. Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). J Clin Oncol 33(suppl 7), 2015.
50. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Hodges S, Lim ZD Jonasch E, Khakoo AY, Tannir NM. Circulating cytokines and angiogenic factors (CAFs) in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: Results from a phase II clinical trial. J Clin Oncol 33(suppl 7), 2015.
51. Campbell MT, Shay AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7), 2015.
52. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33(suppl 7), 2015.
53. Shah AY, Campbell MT, Nautiyal KD, Hashemi N, Matin SF, Vaporciyan AA, Rhines LD, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CG, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7), 2015.
54. Malouf G, Zhang J, Tannir NM, Thompson E, Spano JP, Khayat D, Su X. Charting DNA methylation of long non-coding RNA in clear-cell renal cell carcinoma. J Clin Oncol 33(suppl 7), 2015.
55. Shah AY, Karam JA, Rao, P, Jonasch E, Rathmell K, Matin SF, Vaishampayan UN, Heng D, Plimack ER, Guancial EA, Fung C, Lowas SR, Lim ZD, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients. J Clin Oncol 33(suppl 7), 2015.
56. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Hoang A, Efstathiou E, Liu XD, BAi S, German P, Zhou L, Jonasch D, Zhang X, Conti CJ, Tannir NM, Eissa NT, Mills GB, Walker CL. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 74(suppl 19), 2014.
57. Tannir NM, Jonasch E, Altinmakas Emre, Ng CS, Qiao W, Tamboli P, Rao P, McDermott DF, Wood CG, Choueiri T. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 32(5s):suppl, 2014.
58. Gao J, Yao H, Su X, Rao P, Sharma P, Karam JA, Wood CG, Tannir NM. Molecular characterization of renal medullary carcinoma (RMC). J Clin Oncol 32(5s):suppl; abstr 4586, 2014.
59. Malouf G, Zhang J, Tannir NM, Erika Thompson E, S J-P, Khayat D, Su X. Association of CpG island methylator phenotype with clear-cell renal cell carcinoma aggressiveness. J Clin Oncol 32(5s), 2014.
60. Nieto Y, Tu S-M, Jones RB, Tannir NM, Bassett RL, Margolin DA, Holmberg L, Champlin RE, Pagliaro LC. Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT). J Clin Oncol 32(5s), 2014.
61. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin S-H, Logothetis C, Tu S-M. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32(suppl), 2014.
62. Karam JA, Devine CE, Urbauer DL, Lozano M, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. J Clin Oncol 32(suppl 4), 2014.
63. Malouf GG, Zhang J, Tannir N, Thompson EJ, Khayat D,Spano J-P, Su X. Long non-coding RNA subtype classification of clear-cell renal cell carcinoma. Cancer Res 74(Suppl 19), 2014.
64. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Bai S, German P, Zhang X, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Tannir NM, Sircar K. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Eur J Cancer 20(suppl 6):172, 2014.
65. Sun M, Monzon FA, Zhou L, Liu X, Ding Z, Zhang X, Bai S, German P, Kalra S, Park, IY, Dere R, Berry T, Tong X, Walker C, Tannir NM, Matin S, Fuller G, Mccutcheon IE, Liu XD. Identification of molecular drivers of human hemangioblastoma. Cancer Res 74(suppl 19), 2014.
66. Melkonian S, Daniel CR, Hildebrandt M, Tannir NM, Ye Y, Chow WH, Wood C, Wu X. Established genetic variants and dietary patterns jointly impact risk of renal cell carcinoma in non-Hispanic whites. Cancer Res 74(Suppl 19), 2014.
67. Wang X, Melkonian S, Gu J, Chang D, Tannir NM, Wood C, Wu X. Mitochondrial DNA copy number in peripheral blood and the risk of clear-cell renal cell carcinoma: Effect of age, gender, smoking, and history of hypertension. Cancer Res 74(suppl 19), 2014.
68. Zhou L, Liu X, Sun M, Tannir NM, Laird D, Liu XD. The mechanisms of anti-VEGF therapy resistance in renal cell carcinoma. Cancer Res 74(suppl 19), 2014.
69. Kim DY, Wood CG, Busch A, Qiao W, Tamboli P, Jonasch E, Tannir NM, Matin SF, Karam JA. Survival and prognostic variables predicting survival in T4 renal cell carcinoma. J Urol 191(4):e386-7, 2014.
70. Kalra S, Atckinson BJ, Matrana MR, Matin SF, Wood CG Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir, NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. J Clin Oncol 32(suppl 4), 2014.
71. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Cron PG, Tannir NM, Jonasch E.. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. J Clin Oncol 32(suppl 4), 2014.
72. Matrana MR, Baiomy A, Elsayes KM, Shetty A, Teegavarapu PS, Xiao L, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic non-clear-cell renal cell carcinoma (nccRCC) treated with pazopanib. J Clin Oncol 32(suppl 4), 2014.
73. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Tannir NM. Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32(suppl 4), 2014.
74. Jardim DLF, Gagliato DDM, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Piha-Paul SA, Ru S, Tannir NM, Corn PG, Tang C, Hess KR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. J Clin Oncol 32(suppl 4), 2014.
75. Matrana M, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy. Ann Oncol 24:2779, 2013.
76. Cauley DH, Atkinson BJ, Ng CS, Millikan RE, Xiao L, Corn PG, Jonasch E, Tannir NM. mTOR inhibitor-associated noninfectious penumonitis in patients with metastatic renal cell cancer: a single-center experience. J Clin Oncol 31(Suppl), 2013.
77. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Joneasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single -center experience. J Clin Oncol 31(Suppl), 2013.
78. Yennurajalingam S, Reddy AS, Tannir NM, Lee RT, Lopez G, Escalante C, Manzullo EF, frisbee-Hume S, Tarleton K, Williams JL, Palla SL, Cohen L, Bruera E. High dose Asian ginseng, (Panax Ginseng) for cancer related fatigue (CRF): A preliminary report. J Clin Oncol 31(Suppl), 2013.
79. Karam JA, Devine CE, Lozano M, Tannir NM, Ahrar K, Tamboli P, Wood CG. A phase II clinical trial examining the impact of neoadjuvant axitinib on primary tumor response in patients with locally advanced clear cell renal cell carcinoma. J Clin Oncol 31(suppl), 2013.
80. Jonasch E, Corn PG, Pagliaro LC, Lara P, Wang X, Do KA, Garza R, Bird S, Drabick JJ, Marcott V, Quinn D, Doyle A, Tannir NM. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol 31(suppl), 2013.
81. Malouf GG, Su X, Yao H, Wood CG, Lu Y, Liang S, Thompson EJ, Doss DJ, Jelinek J, Issa JP, Tannir NM. Integrated transcriptome and methylome sequencing of Xp11 translocation renal cell carcinomas reveal uncoupling of DNA methylation and transcriptional profiles. Can Research 73(Suppl 8), 2013.
82. Yetil A, Jonasch E, Wang X, Wood C, Matin S, Tran HT, Tannir NM, Heymach JV, Zurita AJ. Plasma cytokine and angiogenic factor (CAF) profiling for identification of markers associated with clinical benefit from bevacizumab (BEV) and with primary tumor presence in a phase II presurgical study of metastatic renal cell carcinoma (mRCC) patients. Cancer Res 73(suppl 8), 2013.
83. Parker PA, Alba F, Fellman B, Urbauer D, Li Y, Ng C, Karam JA, Tannir NM, Liu XD, Wood C, Matin S. Role of uncertainty on quality of life (QOL) in patients with localized renal tumors on active surveillance (AS): A prospective 2-year study. J Urol 189(4), 2013.
84. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updates results. J Clin Oncol 31(suppl 6), 2013.
85. Thompson JA, Forero A, Heath EI, Pal SK, Ansell SM, Infante JR, De Vos S, Hamlin PA, Whiting NC, Zhao B, Tannir NM. SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6), 2013.
86. Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. J Clin Oncol 31(suppl 6):abstr 381, 2013.
87. Babaian K, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6), 2013.
88. Conter HJ, Wood CG, Matin SF, Tamboli P, Millikan RE, Jonasch E, Tannir NM. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. J Clin Oncol 31(suppl 6), 2013.
89. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do K-A, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol 31(suppl 6), 2013.
90. Merrill MM, Wood CG, Tannir NM, Slack R, Babaian K, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 31(suppl 6), 2013.
91. Kenney P, Karam J, Levey R, Nogueras-Gonzalez G, Matin S, Tamboli P, Tannir N, Wood C. Clinical predictors for the development of pulmonary metastases among RCC patients with indeterminate pulmonary nodules. J Urol 189(4), 2013.
92. Jonasch E, Thakur S, Sircar K, Tamboli P, Tannir NM, Monzon FA. Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. J Clin Oncol 31(suppl 6), 2013.
93. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Kydema K, Petillo D, Teh BT, Tannir NM, Hung MC, Jonasch E. Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl), 2012.
94. Burnight T, Wood CG, Tannir NM, Jonasch E, Pisters LL, Matin SF, Spelman A, Wei Q, Cohen. A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). J Clin Oncol 30(Suppl), 2012.
95. Nieto Y, Tannir NM, Tu S-M, Jones RB, Zurita AJ, Aparicio A, Bassett R, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC. Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). J Clin Oncol 30(Suppl), 2012.
96. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol 30(Suppl), 2012.
97. Haddad H, Rini BI, Jonasch E, Tannir NM, Dreicer R, Garcia JA, Wood LS, Elson P. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30(Suppl), 2012.
98. Cohen L, Tannir NM, Liu XD, Pisters L, Matin S. Spelman A, Wei Q, Wood C. Short- and long-term effects of expressive writing in patients with renal cell carcinoma. BMC Compl and Alt Med 12(1), 2012.
99. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E. Reduction of Cancer-Related Fatigue with Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Oncol 30(suppl), 2012.
100. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Obesity, weight gain, physical activity and polymorphism in mTOR pathway and risk of renal cell carcinoma. Cancer Res 72(suppl 8), 2012.
101. Aparicio A, Sun J, Tang DN, Arap W, Araujo J, Corn, P, Tannir NM, Wang X, Siefker-Radtke A, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Res 72(suppl 8), 2012.
102. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge K, Dykema K, Petillo D, Teh BT, Tannir NM, Jonasch E, Hung MC. SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC). Cancer Res 72(suppl 8), 2012.
103. Kenny P, Chapin B, Culp S, Richey S, Nogueras-Gonzalez G, Tamboli P, Tannir NM, Wood C. Does cytoreductive nephrectomy improve survival in non-clear cell renal cell carcinoma?. J Urol, 2012.
104. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 30(Suppl 5), 2012.
105. Flaherty A, Matrana MR, Atkinson BJ, Tannir NM. Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series. J Clin Oncol 30(Suppl 5), 2012.
106. Matrana MR, Rao P, Atkinson BJ, Guo C, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience. J Clin Oncol 30(Suppl 5), 2012.
107. Chapin BF, Delacroix SE, Kenney PA, Nogueras Gonzalez GM, Tamboli P, Jonasch E, Tannir NM, Wood CG. Nodal disease in the setting of metastatic renal cell carcinoma: Can a lymph node dissection alter outcomes?. J Clin Oncol 30(Suppl 5), 2012.
108. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Dykema K, Petillo D, Teh BT, Tannir NM, Hung M-C, Jonasch E. Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl 5), 2012.
109. Malouf G, Monzon FA, Couturier J, Molinie V, Escudier BJ, Camparo P, Tamboli P, Wood CG, Tannir NM. Genomic analysis of translocation renal cell carcinoma: Association of frequent 3p loss and poor outcome. J Clin Oncol 30(Suppl 5), 2012.
110. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E. Dexamethasone (DM) for cancer-related fatigue: A double -blinded, randomized, placebo-controlled trial. J Clin Oncol 30(Suppl):abstr 9002, 2012.
111. Petillo D, Ho T, Monzon FA, Hoang A, Tampoli P, Furge K, Dykema K, Teh BT, Tannir NM, Hung MC, Liu XD. Identifying SETD2-epigenetically regulated pathways to target kidney cancer metastases. BJU Int 110(suppl 2):17, 2012.
112. Atkinson B, Kalra S, Wang X, Tannir NM, Jonasch E. Improved outcomes with sunitinib alternative schedule compared to traditional schedule: A single-center retrospective review. BJU Int 110(suppl 2):2, 2012.
113. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Line AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C, Prostate Cancer Clinical Trials Consortium. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29(Suppl), 2011.
114. Jonasch E, Lara P, Tannir NM. A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727). J Clin Oncol 29(suppl), 2011.
115. Posadas EM, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD. Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. J Clin Oncol 29(suppl), 2011.
116. Monson FA, Alvarez K, Peterson L, Tannir NM, Jonasch E. Chromosome 14q loss leads to haploinssuficiency of HIF-1a and poor outcomes in metastatic clear cell renal cell carcinoma. Cancer Res 71(suppl 8), 2011.
117. Chapin BF, Delacroix SE, Culp SH, Nogueras-Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Post-operative complications from cytoreductive nephrectomy after pre-surgical targeted threapy for metastatic renal cell carcinoma. J Urol 185(4), 2011.
118. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol 29(suppl 7), 2011.
119. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 29(suppl 7), 2011.
120. Tannir NM, Lim ZD, Rao P, Tamboli P, Atkinson B, Vaishampayan U, Plimack E, Rathmell K, Jonasch E. Outcome of patients with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 29(suppl 7), 2011.
121. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29(suppl 7), 2011.
122. Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. J Clin Oncol 29(suppl 7), 2011.
123. Verma J, Jonasch E, Allen P. Tannir NM, Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. J Clin Oncol 29(suppl 7), 2011.
124. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 29(suppl 7), 2011.
125. Abel E, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Use of early primary tumor response to predict overall survival in patients with metastatic RCC undergoing treatment with sunitinib. J Clin Oncol 29(suppl 7), 2011.
126. Mahajan A, Verma JA, Jonasch E, Tannir N, Allen PK. Tyrosine kinase inhibitors and the treatment of brain metastases in metastatic renal cell carcinoma. Amer Radium Soc SS01(CNS Cancer):Abstract ID: 35411, 2011.
127. Chapin BF, Wood CG, Jonasch E, Tannir N, Tamboli P, Culp SH, Delacroix SE, Gonzalez G. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. J Urol 185(suppl 4), 2011.
128. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Early primary tumor response is an independent predictor of overall survival in patients with metastatic RCC undersgoing treatment with sunitinib. J Urol 185(suppl 4), 2011.
129. Margulis V, Matin S, Jonash E, Tamboi P, Tannir NM, Swanson D, Wood C. Impact of delay from diagonsis to cytoreductve nephrectomy on oncologic outcomes of patients with metastatic renal cell carcinoma. J Urol 183(4), 2010.
130. Abel EJ, Culp S, Tannir NM, Matin S, Jonasch E, Wood CG. Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?. J Urol 183(4), 2010.
131. Karam J, Varella L, Garcia J, Dreicer R, Campbell S, Jonasch E, Tannir NM, Rini B, Wood C. Metastasectomy following targeted therapy in patients with renal cell carcinoma. J Urol 183(4), 2010.
132. Karam JA, Ahrar K, Jonasch E, Tannir NM, Vikram R, Romero C, Wood CG Matin SF. Radiofrequency ablation (RFA) of renal tumors: Clinical, radiographic, and pathologic results from a tertiary cancer centre. Eur Urol 9(2), 2010.
133. Pagliaro LC, Tannir NM, Thall PF, Ashe R, Perez CA, Jonasch E. Phase II study of bevacizumab, gemcitabine, and capecitabine treatment for metastatic or unresectable sarcomatoid renal cell carcinoma (SRCC), 2010.
134. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 28(15s):suppl; abstr 4613, 2010.
135. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol 28(15s):suppl; abstr 4606, 2010.
136. Atkinson BJ, Perpich J, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J Clin Oncol 28:suppl; abstr e15115, 2010.
137. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol 28(15s):suppl; abstr 4604, 2010.
138. Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J Clin Oncol 28(15s):suppl; abstr 4601, 2010.
139. Tannir NM, Wong Y, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, E. M. Posadas, Qian J, Ricker JL, Michaelson D. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol 28(15s):4527, 2010.
140. Wilhelm KL, Atkinson BJ, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15047, 2010.
141. Monzon FA, Alvarez K , Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15012, 2010.
142. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol 28:suppl; abstr e15083, 2010.
143. Matin SF, McCutcheon IE, Gombos DS, S. Waguespack, N. M. Tannir, Wen S, Davis DW, Smith LA, Fuller G, Jonasch E. Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. J Clin Oncol 28(15s):3040, 2010.
144. Tannir NM, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure. EJC Suppl 7(2), 2009.
145. Lin J, Wood C, Yang H, Clague J, Matin S, Tannir N, Tamboli P, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Can Research 69(suppl 9), 2009.
146. Wu HK, Jonasch E, Wood C, Tannir NM, Matin S, McKee KS, Heymach JV, Zurita AJ. Circulating endothelial cells (CEC) and progenitors (CEP) and VEGFR-1-expressing monocytes as biomarkers for patients (pts) with renal cell carcinoma (RCC). Can Research 69(suppl 9), 2009.
147. Culp SH, Abel EJ, Margulis V, Bill KL, Tampoli P, Jonasch E, Matin SF, Swanson DA, Tannir NM, Wood CG. Identifying patients with metastatic renal cell carcinoma who will not benefit from cytoreductive nephrectomy. J Urol 181(suppl 4):498, 2009.
148. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol 27:suppl; abstr e16035, 2009.
149. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s):suppl; abstr 5004, 2009.
150. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s):spllu; abstr 5114, 2009.
151. Falchook GS, Wheler JJ, Tannir NM, Maing A, Jackson EF, Hong D, Lawhorn KN, Ng CS, Amin H, Kurzrock R. Hypoxia-inducible factor 1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol 27(15s):suppl; abstr 3555, 2009.
152. Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S. Pagliaro LC, Dinney C, Millikan RE. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 27(15s):suppl; abstr 5071, 2009.
153. Montero AJ, Diaz-Montero CM, Liu J, Do K, Millikan RE, Tannir NM. Cytokines and angiogenic factors in metastatic renal cell cancer: Association of pre-treatment serum levels with survival. J Clin Oncol 27:suppl; abstr e16036, 2009.
154. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27:suppl; abstr e16112, 2009.
155. Atkinson B, Hart J, Lin E, Tannir N, Jonasch E. Patient characteristics associated with dose-limiting sunitinib adverse events. J Clin Oncol 27:suppl; abstr e16110, 2009.
156. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27:suppl; abstr e16096, 2009.
157. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 27(15s):suppl; abstr 5036, 2009.
158. Shao L, Lin J, Matin S, Tannir NM, Wood CG Wu X. FAmilial risk of kidney cancer. Ann Epidemiology 18(9), 2008.
159. Clague J, Lin J, Matin S, Tannir N, Wood C, Wu X. Familial risk of kidney cancer. Can Research 68(suppl 9), 2008.
160. Chen M, Ye Y, Yang H, Matin S, Tannir N, Wood C, Gu J, Wu X. Genome-wide profiling of chromosomal aberrations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Can Research 68(suppl 9), 2008.
161. Zurita A, Jonasch E, Du D, Yan S, Wang X, Xu L, Herynk M, McKee K, Tran H, Tannir N, Heymach J. Cytokine and angiogenic factor (CAF) profiling for prediction of outcome to first line sorafenib (SR) versus SR plus low-dose interferon-α (IFNα) in patients with advanced renal cell carcinoma (mRCC). Can Research 68(suppl 9), 2008.
162. Nadler L, Haining N, Drury L, Enzinger P, Russell K, Weems G, Hughes L, Luby T, Matijevic M, Ramesh R, Hedley ML, Gong J, Tannir N, Hong D, Kurzrock R. Anti-CYP1B1 biologic and clinical responses are induced in patients with advanced stage solid tumors with cyclophosphamide pre-dosing and immunization with ZYC300. Can Research 68(suppl 9), 2008.
163. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro L, Corn P, Aparicio A, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26:5093, 2008.
164. Dubauskas Z, Kunishige J, Prieto VG, Hwu P, Jonasch E, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: A single institution experience. J Clin Oncol 26:16101, 2008.
165. Araujo JC, Jonasch E, Tannir NM, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26:5106, 2008.
166. Tsavachidou D, Tannir NM, Thomas C, Mills GB, Jonasch E. Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma. J Clin Oncol 26:16016, 2008.
167. Pagliaro LC, Tannir NM, Tu S, Moomey B, Carter CM, Bekele N, Mathew P. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol 26:13545, 2008.
168. Falchook GS, Jackson EF, Wheler JJ, Moulder SL, Hong DS, Naing A, Tannir NM, Lawhorn KN, Ng CS, Kurzrock R. Anti-angiogenic therapy in combination with hyposix-inducible factor-1α (HIF-1α) modulation. J Clin Oncol 26:14604, 2008.
169. Jonasch E, Wood CG, Matin S, Tamboli P, Do K. Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26:5104, 2008.
170. Mathew P, Pagliaro LC, Tannir NM, Tu S, Marcott V, Patterson L, Reed K, Bekele N, Logothetis CJ. Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases. J Clin Oncol 26:5164, 2008.
171. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26:5112, 2008.
172. Liu H, Wood C, Lin J, Matin S, Tannir N, Wu X. Dietary folate intake and risk of renal cell carcinoma: a case-control analysis. Can Research 67(suppl 9), 2007.
173. Camacho LH, Hong DS, Gutierrez C, Parker CA, Purdom MA, Tannir NM, Moulder S, Gale RP, Schwartz B, Kurzrock R. Organic arsenic in patients (pts) with advanced solid tumors: Phase 1 results of Z10-101 (s-dimethylarsino-glutathione). J Clin Oncol 25(18S):Abstract 3554, 2007.
174. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 15522, 2007.
175. Matin S, Tannir N. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Clin Oncol 25(Moderated Poster Acceptance):Abstract 97323, 2007.
176. Jonasch E, Corn P, Ashe RG, Do D, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 5104, 2007.
177. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients for advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25(18S):Abstract 5033, 2007.
178. Hong DS, Camacho L, Ng C, Wright J, Newman RA, Moulder S, Tannir N, Wheler J, Khan R, Kuzrock R. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant U01 CA062461). J Clin Oncol 25(18S):Abstract 3549, 2007.
179. Jonasch E, TsavachidouD, Wood C, Tamboli P, Tu S, Thomas C, Do KA, Matin S, McDonnell T, Tannir NM. Presurgical treatment of metastatic renal cell carcinoma patients with bevacizumab and erlotinib: preliminary efficacy and biomaker data. EJC Suppl 4(12):80, 2006.
180. Shao L, Wood CG, Zhang D, Tannir NM, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a predisposition factor for renal cancer. Can Research 66(suppl 8), 2006.
181. Camacho LH, Hong DS, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA, Lewis J, Gale RP, Kurzrock R. Phase 1 trial of Z10-101, a novel organic arsenic in patients with advanced cancers. J Clin Oncol 24:Abstract 13041, 2006.
182. Spiess PE, Brown GA, Liu P, Tannir NM, Tu S, Kamat AM, Pisters LL. Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 24(18S):Abstract 4593, 2006.
183. Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M.D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):Abstract 14538, 2006.
184. Montero AJ, Diaz-Montero C, Wang X, McIntyre BW, Tannir N. Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa). J Clin Oncol 24:Abstract 14503, 2006.
185. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, General R, Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: A phase II study. J Clin Oncol 23(16S):Abstract 4769, 2005.
186. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure. J Clin Oncol 23:Abstract 4750, 2005.
187. Tannir NM, Jonasch E, McMichael C, Wang X, Wooten L, Ng CS. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mrcc) previously treated with immunotherapy. J Clin Oncol 23(16S):Abstract 4598, 2005.
188. Ebinghaus SW, Hussain M, Tannir NM, Gordon MS, Desai AA, Knight RA, Carlson DM, Giflin RA. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol 23(16S):Abstract 4607, 2005.
189. Siefker-Radtke AO, Thall PF, Tannir NM, Tu SM, Pagliaro, LC, Williams DL, Millikan, RE. Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M D Anderson Cancer Center. J Clin Oncol 22(14S):Abstract 4543, 2004.
190. Tannir NM, Cohen L, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as frontline therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):Abstract 4607, 2004.
191. Daliani D, Dieringer P, Matthew P, Pagliaro L, Davies K, Tannir NM, Chen I, Jonasch E, Papandreou C, Logothetis C.. A tolerance and efficacy study of thalidomide, paclitaxel, estramustine combination for patients with chemotherapy refractory androgen independent prostate carcinoma. EJC Suppl 1(5):s261, 2003.
192. Ueno NT, Cheng YT, Giralt SA, RondÓn G, Gajewski JL, Tannir NM, Pagliaro LC, Hortobagyi GN, Champlin RE. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC). J Clin Oncol 20:Abstract #1659, 2002.

Book Chapters

1. Campbell MT, Jonasch E, Woods CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw Hill, 733-751, 2016.
2. Shafaee MN, Tannir NM, Pagliaro LC. Testicular Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw Hill, 807-825, 2016.
3. Matrana M, Atkinson B, Tannir NM. Combinatorial and sequential targeted therapy in metastatic renal cell carcinoma. In: Kidney Cancer. Principles and Practices. Springer-Verlag Berlin: Berlin Heidelberg Germany, 225-239, 2012.
4. Dayyani F, Tannir NM. Targeted Genitourinary Cancers. In: Targeted Therapy for Solid Tumors and Hematologic Malignancies. Cancer Etiology, Diagnosis and Treatments. Nova Science Publishers, Inc, 187-211, 2011.
5. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir MN. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. In: Hematology/Oncology Clinics of North America: Renal Cell Cancer. 4. W. B. Saunders Company, 853-869, 2011.
6. Jonasch E, Matin SF, Pagliaro LC, Wood CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology. Second. McGraw Hill Medical, 905-23, 2011.
7. Brooks HD, Pagliaro LC, Lim ZD, Pisters LL, Tannir NM. Germ Cell Tumors. In: The MD Anderson Manual of Medical Oncology. Second. McGraw Hill Medical, 983-1002, 2011.
8. Kovitz C, Spiess PE, Tannir NM. Germ Cell Tumors. In: Encyclopedia of Cancer. Third. Springer: Germany, 2011.
9. Psiess PE, Tannir NM, Pisters LL. Urogenitary Tract Cancer. In: Methods of Cancer Diagnosis, Therapy, and Prognosis. Springer: Netherlands, 167-179, 2010.
10. Kovitz C, Spiess PE, Tannir NM. Germ Cell Tumors. In: Encyclopedia of Cancer. Second. Springer: Germany, 2009.
11. Jonasch E, Tannir NM. Targeted Therapy in Renal Cell Carcinoma. In: Targeted Cancer Therapy. Humana Press: Totowa, NJ, 305-316, 2008.
12. Tannir N, O'Brien S, Keating M. Diagnosis and treatment of chronic lymphocytic leukemia. In: Neoplastic Diseases of the Blood. Fourth, 83-95, 2003.
13. Tannir N, O'Brien S. Chronic Leukemias. In: Conn's Current Therapy: Latest Approved Methods Of Treatment For The Practicing Physician, 426-434, 2002.
14. Spitzer G, Zander A, Tannir N. Autologous bone marrow transplantation in human solid tumors. In: Recent Advances in Bone Marrow Transplantation. The UCLA Symposium on Molecular and Cellular Biology. New Series. Alan R. Liss, Inc: New York, 615-642, 1983.
15. Masterson J, Fisch M and Tannir N. Palliative interventions. In: Renal Cancer. Oxford University Press: Cambridge, UK.

Books (edited and written)

1. Malouf GG, Tannir NM. Rare Kidney Tumors; Comprehensive Multidisciplinary Management and Emerging Therapies. First. Springer: Switzerland, 2019.
2. Wu X, Shu X, Chow W-H, Gu J, Rao P, Tamboli P, Ho TH, Dere R, Walker CL, Kalra S, Jonasch E, Sabir SH, Tam AL, Matin SF, Kim DY, Karam JA, Wood CG, Gayed BA, Margulis V, Gunturi A, McDermott DF, Eisen T, Skoulidis F, Pal SK, Choueiri TK, Chism DD, Rathmell WK, Atkinson B, Cauley D, Ghia AJ, Choi S, Yennurajalingam S, Chaoul A, Lopez G, Lee R, Garcia MK, Cohen L, Philips GK, Atkins MB. Renal Cell Carcinoma. In: Oxford American Oncology Library. Ed(s) Nizar M. Tannir. First. Oxford University Press: United States of America, 2014.

Letters to the Editor

1. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of clinical stage I testicular cancer: How should we define success?. J Clin Oncol 33: 2321-2, 2015.
2. Tannir NM, Thall P, Millikan RE. Reply from Authors re: Camillo Porta. How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. Eur Urol 2012;62:1020-1: Research in Rare Tumors: A Need for a Paradigm Shift. Eur Urol 62: 1022, 2012.
3. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?. Ann Oncol 22: 1243, 2011.
4. Tannir N, Cabanillas F. Bone Marrow Transplantation and Salvage Chemotherapy. J Clin Onc 1: 64, 1984.